Vanguard Capital Management
SGMT icon

Vanguard Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Vanguard Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8M Buy
2,566,272
+1,467,353
+134% +$9.98M ﹤0.01% 2452
2026
Q1 		$5.74M Buy
+1,098,919
New +$6.12M ﹤0.01% 3001

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's SGMT Position: Q2 2026 in Review

Vanguard Capital Management increased its Sagimet Biosciences (SGMT) stake by 134% in Q2 2026, buying an estimated $9.98M and bringing the position to 2,566,272 shares worth $19.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

Vanguard Capital Management first reported a position in SGMT in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Vanguard Capital Management held 2,566,272 shares of Sagimet Biosciences worth $19.8M as of Q2 2026.
  • Vanguard Capital Management bought 1,467,353 Sagimet Biosciences shares in Q2 2026, an estimated $9.98M.
  • Sagimet Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2452 holding.
  • Vanguard Capital Management first reported a position in Sagimet Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.